← Back to Search

Other

200 mg BMS-984923 for Alzheimer's Disease

Phase 1
Waitlist Available
Led By Adam Mecca, MD, PhD
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 hours after last dose
Awards & highlights

Study Summary

Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 hours after last dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 hours after last dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Area Under the Curve From 0 to 24h (AUC 24h)
Count of Clinically Significant Changes in Safety Assessments
Count of Lab Abnormalities
+3 more
Secondary outcome measures
Receptor Occupancy

Side effects data

From 2022 Phase 1 trial • 36 Patients • NCT04805983
17%
Blood pressure increased
17%
Headache
17%
Blood triglycerides increased
100%
80%
60%
40%
20%
0%
Study treatment Arm
10 mg BMS-984923
150 mg BMS-984923
40 mg BMS-984923
70 mg BMS-984923
100 mg BMS-984923
200 mg BMS-984923

Trial Design

6Treatment groups
Experimental Treatment
Group I: 70 mg BMS-984923Experimental Treatment1 Intervention
Group II: 40 mg BMS-984923Experimental Treatment1 Intervention
Group III: 200 mg BMS-984923Experimental Treatment1 Intervention
Group IV: 150 mg BMS-984923Experimental Treatment1 Intervention
Group V: 100 mg BMS-984923Experimental Treatment1 Intervention
Group VI: 10 mg BMS-984923Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BMS-984923
2021
Completed Phase 1
~40

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,852 Previous Clinical Trials
2,738,405 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,675 Previous Clinical Trials
28,020,849 Total Patients Enrolled
Adam Mecca, MD, PhDPrincipal Investigator - Assistant Professor of Psychiatry; Associate Director, Alzheimer's Disease Research Unit; Faculty, Alzheimer's Disease Research Center (ADRC)
Yale University
1 Previous Clinical Trials
50 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Iowa
Texas
Other
New Jersey
How old are they?
18 - 65
65+
What site did they apply to?
Yale University
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria

How responsive is this trial?

Typically responds via
Email
Recent research and studies
clinicaltrials.govStudy
Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923
Adam Mecca 2021. "Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04805983.
~9 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top